Im not too concerned about Geron and their hold. Comparing apples to oranges pretty much. Theirs is a case of problems with lab tests. Once ACT shows there are no adverse affects from the treatment, then its a go. ACT has a really good chance at getting the go-ahead once questions are answered, and Im pretty sure the FDA will have some questions before giving approval. As has been stated before, that's pretty typical procedure for the FDA to do that and no reflection on ACT or the treatment.
News 
Market Data 
Discover 
AI
